Northern Trust Corp Buys 19,681 Shares of ADMA Biologics Inc $ADMA

Key Points

• Northern Trust Corp has increased its stake in ADMA Biologics by acquiring an additional 19,681 shares, bringing its total ownership to approximately 2.59 million shares valued at $51.48 million.
• Insider selling has been noted, with Director Steve Elms selling 194,749 shares for nearly $3.94 million, reflecting a significant decrease in his ownership by 69.04%.
• A number of research firms have differing views on ADMA Biologics, with Raymond James Financial giving it a "strong-buy" rating and increasing the price target to $32.00, while other analysts have downgraded it to a "sell" rating.

Northern Trust Corp lifted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 0.8% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 2,594,756 shares of the biotechnology company's stock after buying an additional 19,681 shares during the quarter. Northern Trust Corp owned about 1.09% of ADMA Biologics worth $51,480,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Brooklyn Investment Group boosted its holdings in shares of ADMA Biologics by 28,655.6% during the first quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock worth $51,000 after acquiring an additional 2,579 shares during the period. Northwest & Ethical Investments L.P. acquired a new stake in shares of ADMA Biologics during the 1st quarter worth $190,000. Raymond James Financial Inc. raised its stake in ADMA Biologics by 18.7% in the first quarter. Raymond James Financial Inc. now owns 1,319,803 shares of the biotechnology company's stock valued at $26,186,000 after purchasing an additional 207,528 shares in the last quarter. State of New Jersey Common Pension Fund D raised its stake in ADMA Biologics by 22.5% in the first quarter. State of New Jersey Common Pension Fund D now owns 124,646 shares of the biotechnology company's stock valued at $2,473,000 after purchasing an additional 22,893 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in ADMA Biologics by 12.7% during the first quarter. American Century Companies Inc. now owns 4,252,362 shares of the biotechnology company's stock worth $84,367,000 after purchasing an additional 478,800 shares during the period. Institutional investors own 75.68% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ADMA. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial upped their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $27.67.

ADMA Biologics Price Performance

ADMA Biologics stock traded down $0.12 during mid-day trading on Monday, reaching $17.26. The company had a trading volume of 2,527,726 shares, compared to its average volume of 3,391,207. The business has a fifty day simple moving average of $17.76 and a 200 day simple moving average of $18.93. The company has a market cap of $4.12 billion, a P/E ratio of 20.07 and a beta of 0.54. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. During the same period in the prior year, the business earned $0.13 earnings per share. The company's revenue for the quarter was up 13.8% compared to the same quarter last year. On average, equities research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In related news, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares in the company, valued at $1,767,559.20. This trade represents a 69.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the sale, the director owned 94,830 shares in the company, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 455,621 shares of company stock worth $9,461,633. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.